Merck KGaA (BIT:1MRK)
Italy · Delayed Price · Currency is EUR | Market Cap | 59.26B +22.7% |
| Revenue (ttm) | 21.14B -0.4% |
| Net Income | 2.37B -17.2% |
| EPS | 5.45 -17.3% |
| Shares Out | n/a |
| PE Ratio | 25.00 |
| Forward PE | 16.07 |
| Dividend | 2.20 (1.63%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 139.95 |
| Day's Range | n/a |
| 52-Week Range | 102.35 - 148.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsNews
MilliporeSigma: A Decade of Curiosity: A Mid-Year Look at SPARK's Momentum
NORTHAMPTON, MA / ACCESS Newswire / August 6, 2026 / As MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, celebrates the 10th anniversary of SPARK, its gl...
Merck KGaA Q2 Earnings Call Highlights
Merck KGaA ETR: MRK reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre a...
Merck KGaA (MRK) Raises 2026 Sales Outlook Amid Strong Demand
Merck KGaA (MRK) Raises 2026 Sales Outlook Amid Strong Demand
Merck KGaA Earnings Call Transcript: Q2 2026
Q2 2026 saw robust organic sales and EBITDA pre growth, led by Life Science and Electronics, with raised full-year guidance reflecting strong momentum. Healthcare faced headwinds from U.S. generic competition, but rare diseases and pipeline progress provided offsets. Bio-Techne acquisition and AI-driven semiconductor demand are key growth drivers.
Merck KGaA Quarterly report: Q2 2026
Merck KGaA has published its Q2 2026 quarterly earnings report on August 6, 2026.
Merck KGaA Earnings release: Q2 2026
Merck KGaA released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q2 2026
Merck KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -44.68% and +3.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Merck KGaA Quarterly report: Q2 2026
Merck KGaA has published its Q2 2026 quarterly earnings report on August 6, 2026.
Merck KGaA Earnings release: Q2 2026
Merck KGaA released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q2 2026
Merck KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Germany's Merck KGaA Raises Outlook on Robust Results, Easing Currency Headwinds
The group pointed to stronger demand in the life-science and electronics markets and resilience in its healthcare operations.
Merck KGaA raises profit guidance on momentum in Life Science, Electronics units
Germany's Merck KGaA lifted its earnings guidance range for 2026 on Thursday, citing a further gain in demand for its drug manufacturing supplies and semiconductor materials, while posting bett...
Merck KGaA Slides: Corporate presentation
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Merck KGaA
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical develo...
Merck KGaA Transcript: M&A announcement
The acquisition of Bio-Techne for $73 per share aims to accelerate growth in Life Science by combining complementary portfolios, with EUR 140 million in cost synergies expected within three years. The deal is immediately margin accretive, enhances innovation, and strengthens U.S. presence.
Merck KGaA Slides: M&A announcement
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Merck KGaA Press release: M&A announcement
Merck KGaA issued a press release on June 25, 2026, disclosing material business information to investors.
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.